Skip to main content

CSF kappa light chains and gadolinium-enhancing brain lesions as predictors of response to therapy with interferon beta 1a (Avonex®) in patients with relapsing multiple sclerosis

Publication ,  Conference
Rudick, R; Cookfair, D; Simon, J; Simonian, N; Jacobs, L; Herndon, R; Richert, J; Salazar, A; Fischer, J; Granger, C; Goodkin, D; O'Reilly, K ...
Published in: NEUROLOGY
1998

Duke Scholars

Published In

NEUROLOGY

ISSN

0028-3878

Publication Date

1998

Volume

50

Issue

4

Start / End Page

A342 / A342

Related Subject Headings

  • Neurology & Neurosurgery
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1702 Cognitive Sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rudick, R., Cookfair, D., Simon, J., Simonian, N., Jacobs, L., Herndon, R., … Boyle, S. (1998). CSF kappa light chains and gadolinium-enhancing brain lesions as predictors of response to therapy with interferon beta 1a (Avonex®) in patients with relapsing multiple sclerosis. In NEUROLOGY (Vol. 50, pp. A342–A342).
Rudick, R., D. Cookfair, J. Simon, N. Simonian, L. Jacobs, R. Herndon, J. Richert, et al. “CSF kappa light chains and gadolinium-enhancing brain lesions as predictors of response to therapy with interferon beta 1a (Avonex®) in patients with relapsing multiple sclerosis.” In NEUROLOGY, 50:A342–A342, 1998.
Rudick R, Cookfair D, Simon J, Simonian N, Jacobs L, Herndon R, Richert J, Salazar A, Fischer J, Granger C, Goodkin D, O’Reilly K, Boyle S. CSF kappa light chains and gadolinium-enhancing brain lesions as predictors of response to therapy with interferon beta 1a (Avonex®) in patients with relapsing multiple sclerosis. NEUROLOGY. 1998. p. A342–A342.

Published In

NEUROLOGY

ISSN

0028-3878

Publication Date

1998

Volume

50

Issue

4

Start / End Page

A342 / A342

Related Subject Headings

  • Neurology & Neurosurgery
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1702 Cognitive Sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences